230,022 Shares in NKGen Biotech, Inc. (NYSE:NKGN) Acquired by Kepos Capital LP

Kepos Capital LP bought a new position in NKGen Biotech, Inc. (NYSE:NKGN) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 230,022 shares of the company’s stock, valued at approximately $151,000. Kepos Capital LP owned approximately 0.51% of NKGen Biotech as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of NKGN. Magnetar Financial LLC acquired a new stake in NKGen Biotech in the 4th quarter worth approximately $175,000. Polar Asset Management Partners Inc. boosted its stake in NKGen Biotech by 9.4% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 1,181,872 shares of the company’s stock worth $447,000 after purchasing an additional 101,872 shares in the last quarter. Finally, Sequoia Financial Advisors LLC boosted its stake in NKGen Biotech by 126.1% in the 4th quarter. Sequoia Financial Advisors LLC now owns 156,000 shares of the company’s stock worth $102,000 after purchasing an additional 87,000 shares in the last quarter. 76.17% of the stock is currently owned by institutional investors and hedge funds.

NKGen Biotech Stock Down 17.0 %

NKGN stock opened at $0.16 on Friday. NKGen Biotech, Inc. has a 52 week low of $0.10 and a 52 week high of $2.57. The firm has a 50 day moving average of $0.43 and a 200 day moving average of $0.46. The stock has a market capitalization of $7.19 million, a PE ratio of -0.03 and a beta of 0.45.

About NKGen Biotech

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.